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Examining the use of rapid polymerase chain reaction assay in optimizing
antimicrobial usage in respiratory viral infections.
Deandra Romero, PharmD; Maria Rojo-Carlo, PharmD, BCPS; Ana Lopez-Samblas, PharmD, FSHP

Background

Methods

Preliminary Results

• Respiratory infections account for over 5 million deaths worldwide.
• Historically, respiratory pathogen testing has included the use of
cultures and antigen-testing.
• Rapid polymerase chain reaction (PCR) assay:
• Fast, effective identification of 17 viral pathogens
• 95% sensitive and 99% specific
• Turnaround time ~ 1 hour

• An exploratory analysis using medical chart reviews will be conducted using
daily molecular result reports provided to the pharmacy.
• Inclusion criteria: Adults ≥ 18 years of age who received viral PCR
microbiology testing for respiratory infections between July 1, 2017 and
March 31, 2018.
• Exclusion: Patients with a documented viral respiratory infection 2 weeks
prior to the time of admission.
• Patients will be randomly selected (every 6th patient) for a total population size
of 150 patients.
• Data collection:
1. Viral PCR results (time of results & pathogen identification)
2. Diagnostic labs
1. Procalcitonin level (Y-high, Y-low, N)
2. Influenza A & B antigen testing (Y-positive, Y-negative, N)
3. Initial therapy
1. Antimicrobial and/.or antiviral therapy
2. Time of initial therapy
4. If applicable, antibiotic prescribed and documented indication
5. Therapy modification upon respiratory results
1. Y/N (e.g., discontinuation of antibiotic or start of antiviral
therapy)
2. Time of therapy modification

• Preliminary data demonstrates 26.7% (16/60) of patients who had
PCR assay testing were determined to be positive for a respiratory
viral infection.
• Most reported virus: rhinovirus/enterovirus (10/16, 62.5%).
• In addition to PCR testing, 1 in every 3 patients had an influenza A
& B antigen test (18/60, 30%) and 61.7% had a procalcitonin level.
• Patients who were positive for respiratory viral infections were
managed appropriately taking into account any co-infection.
• When antimicrobial therapy was not indicated, the antimicrobial deescalation time was approximately 4 hrs.
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Pathogens Detected
Adenovirus
• Influenza A/H1
Coronavirus HKU1
• Influenza A/H3
Coronavirus NL63
• Influenza A/H1-2009
Coronavirus 229E
• Influenza B
Coronavirus OC43
• Parainfluenza Virus 1
Human Metapneumovirus
• Parainfluenza Virus 2
Human Rhinovirus/
• Parainfluenza Virus 3
Enterovirus
• Parainfluenza Virus 4
Influenza A
• Respiratory Syncytial Virus

Figure 1. Pathogens detected in the FilmArray® Panel

• Targeted therapies exist only for influenza infections.
• Agents are most effective in reducing patient’s symptoms and
duration of illness if used within 48 hours of symptom onset.
• Other practices have included the use of procalcitonin levels to aid
in the identification of bacterial infections.
• Higher levels are associated with bacterial infections
• Studies:
• FilmArray® respiratory panel resulted in decreased admission
rates, duration of antimicrobial use, length of stay, and amount
of chest imaging performed.
• PCR assay resulted in a decrease in antibiotic usage only in
patients who tested positive for influenza virus.
• Procalcitonin levels and respiratory panel results, alone or in
combination, are seldom associated with the discontinuation of
antibiotic therapy upon diagnosis of viral infection.
• All studies highlight the effectiveness of PCR technology in
identifying viral infections.
• Different findings suggest the need to further evaluate the usefulness
of rapid PCR technology in optimizing antimicrobial therapy in
respiratory infections.
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Figure 3. Antigen testing in sample size (n=60)

Procalcitonin Level

Yes-high: 4
Yes-low: 4
No level: 8

• The objective is to examine the use of viral PCR assays in the
management of respiratory viral infections in a community hospital.
• The study will describe viral PCR use in identifying viral pathogens,
evaluating appropriate treatment, and de-escalating of antimicrobial
therapy when indicated.

• Optimize treatment using PCR assay as a diagnostic tool.
• Reduce unnecessary diagnostic tests.
• Decrease the inappropriate use of antimicrobials in viral respiratory
infections.
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Preliminary Results
Patients with a Positive PCR Result

Conclusion

ABX: 12
Initial Therapy

Antiviral: 1
None: 3

Documented ABX
indication

11

Average De-escalation Time

~ 4 hrs

Figure 2. Positive PCR result data

No, 38.3%
Yes, 61.7%

Figure 4. Procalcitonin level ordered in total
sample size (n=60)
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